Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Cancer Immunology, Immunotherapy : CII
|
June 1, 1996
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
M A Reddish, G D MacLean, S Poppema, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1996
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
G D MacLean, D W Miles, R D Rubens, et al.
Glycoconjugate Journal
|
August 1, 1997
Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes
M A Reddish, L Jackson, R R Koganty, et al.
Cancer Research
|
September 15, 1996
The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer
L H Regimbald, L M Pilarski, B M Longenecker, et al.
Cancer Research
|
November 21, 1998
The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences
B Agrawal, M A Reddish, B Christian, et al.
International Journal of Cancer
|
May 16, 1995
CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy
M B Yacyshyn, S Poppema, A Berg, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
January 9, 1998
Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies
M A Reddish, M R Suresh, R R Koganty, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
January 30, 1999
Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
B M Sandmaier, D V Oparin, L A Holmberg, et al.
International Journal of Cancer
|
February 14, 1998
Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine
J Samuel, W A Budzynski, M A Reddish, et al.
Bioconjugate Chemistry
|
July 21, 1998
Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses
H H Guan, W Budzynski, R R Koganty, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Cancer Immunology, Immunotherapy : CII
|
June 1, 1996
Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy
M A Reddish, G D MacLean, S Poppema, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
July 1, 1996
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide
G D MacLean, D W Miles, R D Rubens, et al.
Glycoconjugate Journal
|
August 1, 1997
Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes
M A Reddish, L Jackson, R R Koganty, et al.
Cancer Research
|
September 15, 1996
The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer
L H Regimbald, L M Pilarski, B M Longenecker, et al.
Cancer Research
|
November 21, 1998
The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences
B Agrawal, M A Reddish, B Christian, et al.
International Journal of Cancer
|
May 16, 1995
CD69+ and HLA-DR+ activation antigens on peripheral blood lymphocyte populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy
M B Yacyshyn, S Poppema, A Berg, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
January 9, 1998
Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies
M A Reddish, M R Suresh, R R Koganty, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
January 30, 1999
Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine
B M Sandmaier, D V Oparin, L A Holmberg, et al.
International Journal of Cancer
|
February 14, 1998
Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine
J Samuel, W A Budzynski, M A Reddish, et al.
Bioconjugate Chemistry
|
July 21, 1998
Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses
H H Guan, W Budzynski, R R Koganty, et al.
Page
of 3